AU769235B2 - Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases - Google Patents
Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases Download PDFInfo
- Publication number
- AU769235B2 AU769235B2 AU42235/00A AU4223500A AU769235B2 AU 769235 B2 AU769235 B2 AU 769235B2 AU 42235/00 A AU42235/00 A AU 42235/00A AU 4223500 A AU4223500 A AU 4223500A AU 769235 B2 AU769235 B2 AU 769235B2
- Authority
- AU
- Australia
- Prior art keywords
- chemical compound
- compound according
- geldanamycin
- hsp
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12859399P | 1999-04-09 | 1999-04-09 | |
| US60/128593 | 1999-04-09 | ||
| PCT/US2000/009512 WO2000061578A1 (en) | 1999-04-09 | 2000-04-07 | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4223500A AU4223500A (en) | 2000-11-14 |
| AU769235B2 true AU769235B2 (en) | 2004-01-22 |
Family
ID=22436066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU42235/00A Ceased AU769235B2 (en) | 1999-04-09 | 2000-04-07 | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7271160B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1169319A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002541255A (cg-RX-API-DMAC7.html) |
| AU (1) | AU769235B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2370007A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000061578A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372712B1 (en) | 1998-05-22 | 2002-04-16 | The Board Of Trustees Of The Leland Stanford Jr. University | Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand |
| US6887842B1 (en) * | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
| US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| AU2044001A (en) | 1999-11-19 | 2001-05-30 | Board Of Trustees Of The Leland Stanford Junior University | Targeted bifunctional molecules and therapies based thereon |
| US20020002169A1 (en) | 1999-12-08 | 2002-01-03 | Griffin John H. | Protein kinase inhibitors |
| US6946456B2 (en) | 2000-07-28 | 2005-09-20 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| ATE328888T1 (de) | 2000-08-25 | 2006-06-15 | Sloan Kettering Inst Cancer | Radicicol und monocillin und ihre analogen und ihre anwendungen |
| US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| US7825094B2 (en) | 2001-05-23 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Method of treatment for cancers associated with elevated HER 2 levels |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| EP1923061A1 (en) | 2001-09-24 | 2008-05-21 | Conforma Therapeutic Corporation | Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins |
| JP2005504086A (ja) | 2001-09-24 | 2005-02-10 | コンフォーマ セラピューティクス コーポレーション | 17−アリルアミノゲルダナマイシン(17−aag)および他のアンサマイシン類を製造する方法 |
| GB0202871D0 (en) * | 2002-02-07 | 2002-03-27 | Cancer Res Ventures Ltd | Assays,methods and means |
| US7259156B2 (en) | 2004-05-20 | 2007-08-21 | Kosan Biosciences Incorporated | Geldanamycin compounds and method of use |
| KR20070050918A (ko) * | 2004-07-02 | 2007-05-16 | 뉴텍 파마 피엘씨 | 암의 치료 |
| US20060105941A1 (en) * | 2004-11-12 | 2006-05-18 | Allergan, Inc. | Mixed antibiotic codrugs |
| BRPI0609509A2 (pt) | 2005-03-30 | 2010-04-13 | Conforma Therapeutics Corp | composto ou um polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso do composto, polimorfo, solvato, tautÈmero, enanciÈmero, pró-droga ou sal farmaceuticamente aceitável |
| ES2645095T3 (es) | 2006-06-30 | 2017-12-04 | Sloan-Kettering Institute For Cancer Research | Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90 |
| US20100113355A1 (en) | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| WO2010028389A1 (en) * | 2008-09-08 | 2010-03-11 | The Methodist Hospital Research Institute | Image-guided energy deposition for targeted drug delivery |
| PT2486039T (pt) | 2009-10-07 | 2016-09-06 | Sloan Kettering Inst For Cancer Res | Derivados de purina úteis como inibidores de hsp90 |
| AU2012240077C1 (en) | 2011-04-05 | 2017-08-10 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| MX354215B (es) | 2011-04-05 | 2018-02-19 | Sloan Kettering Inst Cancer Res | Inhibidores de la proteina 90 de choque termico (hsp90). |
| WO2012167261A2 (en) | 2011-06-03 | 2012-12-06 | Yale University | Compositions and methods for treating and preventing neointimal stenosis |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| EP3738594A1 (en) | 2013-09-10 | 2020-11-18 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics having an hsp90 ligand as binding moiety |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| EP3099332A4 (en) | 2014-01-29 | 2017-06-21 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| JP6576942B6 (ja) | 2014-03-03 | 2019-11-27 | マドリガル ファーマシューティカルズ インコーポレイテッド | 標的治療薬 |
| MA39483A (fr) | 2014-03-18 | 2015-09-24 | Synta Pharmaceuticals Corp | Agents thérapeutiques cibles |
| US11377447B2 (en) | 2017-06-20 | 2022-07-05 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| US11491145B2 (en) | 2017-06-20 | 2022-11-08 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
| CN117700313B (zh) * | 2023-12-14 | 2025-02-14 | 怒江绿色香料产业研究院 | 一种羟基十四烯醛及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| JPS55111469A (en) * | 1979-02-19 | 1980-08-28 | Kaken Pharmaceut Co Ltd | Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient |
| US5650430A (en) | 1990-06-06 | 1997-07-22 | Sankyo Company, Limited | Radicicol derivatives, their preparation and their anti-tumor activity |
| CA2052907A1 (en) * | 1990-10-11 | 1992-04-12 | Joseph P. Vacca | Hiv protease inhibitors having symmetrical structure |
| EP0706516A1 (en) * | 1993-06-29 | 1996-04-17 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| NZ331062A (en) | 1996-10-25 | 2000-05-26 | Kyowa Hakko Kogyo Company Ltd | Radicicol derivatives or pharmacologically acceptable salts which show tyrosine kinase inhibition activity and have antitumor effects |
| ATE460423T1 (de) * | 1997-05-14 | 2010-03-15 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
-
2000
- 2000-04-07 AU AU42235/00A patent/AU769235B2/en not_active Ceased
- 2000-04-07 WO PCT/US2000/009512 patent/WO2000061578A1/en not_active Ceased
- 2000-04-07 CA CA002370007A patent/CA2370007A1/en not_active Abandoned
- 2000-04-07 JP JP2000610851A patent/JP2002541255A/ja active Pending
- 2000-04-07 EP EP00921985A patent/EP1169319A4/en not_active Withdrawn
-
2001
- 2001-09-21 US US09/960,665 patent/US7271160B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20020045570A1 (en) | 2002-04-18 |
| WO2000061578A1 (en) | 2000-10-19 |
| JP2002541255A (ja) | 2002-12-03 |
| EP1169319A4 (en) | 2005-02-09 |
| AU4223500A (en) | 2000-11-14 |
| US7271160B2 (en) | 2007-09-18 |
| EP1169319A1 (en) | 2002-01-09 |
| CA2370007A1 (en) | 2000-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7271160B2 (en) | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases | |
| EP3915587B1 (en) | Improved cell-targeting binding molecule | |
| KR960015398B1 (ko) | 신규의 링커를 갖는 안트라사이클린 면역결합체 및 그의 제조방법 | |
| EP3783025A1 (en) | Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof | |
| US6391913B1 (en) | Derivatives of paclitaxel, method for producing same and uses thereof | |
| CA2026147C (en) | Cytotoxic agents comprising maytansinoids and their therapeutic use | |
| TWI662968B (zh) | 配體-細胞毒性藥物偶聯物、其製備方法及其應用 | |
| CA3198788A1 (en) | Camptothecine antibody-drug conjugates and methods of use thereof | |
| JP2018507844A (ja) | 抗体薬物コンジュゲート | |
| EP4671249A1 (en) | CAMPTOTHECINE DERIVATIVE, CONJUGATE OF THE LATTER, ITS PREPARATION PROCESS AND ITS MEDICAL USE | |
| TW200813028A (en) | Improved prodrugs of CC-1065 analogs | |
| US20100029758A1 (en) | Derivatives of isoflavones | |
| Milazzo et al. | ErbB2 targeted epigenetic modulation: anti-tumor efficacy of the ADC trastuzumab-HDACi ST8176AA1 | |
| US20230134986A1 (en) | Glucose triptolide conjugates and uses thereof | |
| CA3184041A1 (en) | Saponin derivatives for use in medicine | |
| US20240398823A1 (en) | Dual inhibitor of histone deacetylase 6 and heat shock protein 90 | |
| US20060052312A1 (en) | Paclitaxel hybrid derivatives | |
| US7238682B1 (en) | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases | |
| JP7054387B2 (ja) | 二官能性プロドラッグ | |
| US20040115209A1 (en) | Compound targeted for specific cells with reduced systemic toxicity | |
| Hong et al. | Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(. beta.-D-arabinofuranosyl) cytosine conjugates of corticosteroids | |
| EP4552655A1 (en) | Antibody-drug conjugates involving erianin and the fabrication methods and applications thereof | |
| Ievoli | Antibody-drug conjugates charged with unconventional payloads | |
| HK40120190A (en) | Antibody-drug conjugates involving erianin and the fabrication methods and applications thereof | |
| CN101374545A (zh) | 消除肿瘤中的异质或混合细胞群体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20010927 |
|
| FGA | Letters patent sealed or granted (standard patent) |